COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy Source: Eur Respir J, 58 (6) 2003969; 10.1183/13993003.03969-2020 Year: 2021
PP240 – COL4A3 degradation is increased in severe, type 2 exacerbating asthmatics Source: ERS Lung Science Conference 2021 Year: 2021
A monoclonal antibody to IL-1B attenuates the late asthmatic response to antigen challenge in patients with mild asthma Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009
Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
An inhaled IGFBP-3 peptide attenuates steroid-resistant neutrophilic bronchial asthma through modulation of ER stress Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019
Tryptase loss-of-function mutations reduce tryptase expression and predict asthmatic response to anti-IgE therapy Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD Year: 2018
Effect of treatment with anti-IgE antibody on airway inflammation in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Relationship between benralizumab exposure and asthma exacerbation rate for patients with severe asthma Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
Overexpression of eNOS suppresses asthmatic features in a mouse model of allergic asthma Source: Eur Respir J 2002; 20: Suppl. 38, 28s Year: 2002
Caspase-1 deficiency reduces eosinophilia and interleukin-33 in an asthma exacerbation model Source: ERJ Open Res, 3 (4) 00047-2017; 10.1183/23120541.00047-2017 Year: 2017
The abnormalities in spontaneous and Fas-induced apoptosis in atopic bronchial asthma (ABA): the key to chronic lung inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 228s Year: 2006
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
The bronchial expression of vanin in moderate to severe asthma Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
HBD-2 mutations are associated with childhood asthma and prophylactic hBD-2 application prevents asthma in mice Source: Virtual Congress 2021 – Paediatric lung disease: novel mechanisms, methods and translational studies Year: 2021
The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007
Treatment with gp120 reduces AHR and airway inflammation in a humanized mouse model of asthma bronchiale Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010